Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Looking for Razors and Needles in a Haystack: Multifaceted Analysis of Suicidal Declarations on Social Media-A Pragmalinguistic Approach.
Ptaszynski M, Zasko-Zielinska M, Marcinczuk M, Leliwa G, Fortuna M, Soliwoda K, Dziublewska I, Hubert O, Skrzek P, Piesiewicz J, Karbowska P, Dowgiallo M, Eronen J, Tempska P, Brochocki M, Godny M, Wroczynski M. Ptaszynski M, et al. Int J Environ Res Public Health. 2021 Nov 9;18(22):11759. doi: 10.3390/ijerph182211759. Int J Environ Res Public Health. 2021. PMID: 34831513 Free PMC article.
A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma.
Shah JJ, Kaufman JL, Zonder JA, Cohen AD, Bensinger WI, Hilder BW, Rush SA, Walker DH, Tunquist BJ, Litwiler KS, Ptaszynski M, Orlowski RZ, Lonial S. Shah JJ, et al. Among authors: ptaszynski m. Cancer. 2017 Dec 1;123(23):4617-4630. doi: 10.1002/cncr.30892. Epub 2017 Aug 17. Cancer. 2017. PMID: 28817190 Free PMC article. Clinical Trial.
A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma.
Chari A, Htut M, Zonder JA, Fay JW, Jakubowiak AJ, Levy JB, Lau K, Burt SM, Tunquist BJ, Hilder BW, Rush SA, Walker DH, Ptaszynski M, Kaufman JL. Chari A, et al. Among authors: ptaszynski m. Cancer. 2016 Nov 15;122(21):3327-3335. doi: 10.1002/cncr.30174. Epub 2016 Jul 19. Cancer. 2016. PMID: 27433944 Free PMC article. Clinical Trial.
First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors.
LoRusso PM, Goncalves PH, Casetta L, Carter JA, Litwiler K, Roseberry D, Rush S, Schreiber J, Simmons HM, Ptaszynski M, Sausville EA. LoRusso PM, et al. Among authors: ptaszynski m. Invest New Drugs. 2015 Apr;33(2):440-9. doi: 10.1007/s10637-015-0211-0. Epub 2015 Feb 17. Invest New Drugs. 2015. PMID: 25684345 Clinical Trial.
A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes.
Garcia-Manero G, Khoury HJ, Jabbour E, Lancet J, Winski SL, Cable L, Rush S, Maloney L, Hogeland G, Ptaszynski M, Calvo MC, Bohannan Z, List A, Kantarjian H, Komrokji R. Garcia-Manero G, et al. Among authors: ptaszynski m. Clin Cancer Res. 2015 Mar 1;21(5):985-94. doi: 10.1158/1078-0432.CCR-14-1765. Epub 2014 Dec 5. Clin Cancer Res. 2015. PMID: 25480830 Free PMC article. Clinical Trial.
A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias.
Khoury HJ, Garcia-Manero G, Borthakur G, Kadia T, Foudray MC, Arellano M, Langston A, Bethelmie-Bryan B, Rush S, Litwiler K, Karan S, Simmons H, Marcus AI, Ptaszynski M, Kantarjian H. Khoury HJ, et al. Among authors: ptaszynski m. Cancer. 2012 Jul 15;118(14):3556-64. doi: 10.1002/cncr.26664. Epub 2011 Dec 2. Cancer. 2012. PMID: 22139909 Free PMC article. Clinical Trial.
Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice.
Desjardins JP, Abbott EA, Emerson DL, Tomkinson BE, Leray JD, Brown EN, Hamilton M, Dihel L, Ptaszynski M, Bendele RA, Richardson FC. Desjardins JP, et al. Among authors: ptaszynski m. Anticancer Drugs. 2001 Mar;12(3):235-45. doi: 10.1097/00001813-200103000-00009. Anticancer Drugs. 2001. PMID: 11290871